In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy
2022 · Science Advances · 174 citations
https://doi.org/10.1126/sciadv.abj6901
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2
Papers
189
Citations
2
h-index
2
i10-index
Hye-Kyung Oh is an academic researcher from ToolGen (South Korea). The author has contributed to research in topics: Virus-based gene therapy research & CRISPR and Genetic Engineering & RNA Interference and Gene Delivery. The author has an h-index of 2, co-authored 2 publications.
ORCID: 0000-0002-8610-4999https://doi.org/10.1126/sciadv.abj6901
https://doi.org/10.1016/j.omtn.2022.08.002
Click to start Chat